ArticleMolecular and clinical oncology2025
Extended progression-free survival after combination treatment with anlotinib and S-1 in refractory advanced esophageal cancer: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rates of survival are low in patients with refractory advanced esophageal cancer in whom chemotherapy, radiotherapy and immunotherapy have failed. In the present report, the case of a 59-year-old male with dysphagia and paraneoplastic leukemoid reaction who was diagnosed with esophageal squamous cell cancer with multiple bone and left adrenal gland metastases, is described. Tumor progression continued after multiline chemotherapy with paclitaxel, platinum and irinotecan; immunotherapy with camrelizumab; and radiotherapy. Furthermore, the patient experienced grade 3 hematologic toxicities and immune-induced myocarditis. As fourth-line therapy, anlotinib was administered in combination with S-1. Thereafter, the patient's progression-free survival was 16.7 months, indicating that anlotinib combined with S-1 may be effective in refractory advanced esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.